Clinical trial
Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up…
NCT03782792 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT03782792 |
|---|---|
| Title | Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis |
| Official title | Effisayil™ 1:Multi-center, Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate Efficacy, Safety and Tolerability of a Single Intravenous Dose of Spesolimab (BI 655130) in Patients With Generalized Pustular Psoriasis (GPP) Presenting With an Acute Flare of Moderate to Severe… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Generalized Pustular Psoriasis |
| Intervention type | Drug |
| Interventions | Spesolimab, Placebo |
| Enrollment | 53 |
| Start date | Jan 31, 2019 |
| Primary completion | Sep 23, 2020 |
| Completion | Jan 5, 2021 |
| First posted | Dec 20, 2018 |
| Last update posted | Oct 16, 2025 |
| Countries | China, France, Germany, Japan, Malaysia, Singapore, South Korea, Switzerland, Taiwan, Thailand, Tunisia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: